-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

605.O2.6 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma

Symposia: Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Apoptosis, Translational Research, Lymphomas, Drug development, Bispecific Antibody Therapy, Non-Hodgkin lymphoma, B Cell lymphoma, Diseases, Indolent lymphoma, Aggressive lymphoma, Treatment Considerations, Biological therapies, Immunology, Lymphoid Malignancies, Non-Biological therapies, Biological Processes, Pharmacology, Molecular biology, Technology and Procedures, Study Population, Pathogenesis, Animal model, Omics technologies
Monday, December 9, 2024: 4:30 PM-6:00 PM
Ballroom 20CD (San Diego Convention Center)
Moderators:
Markus Müschen, MD, Yale University and Piers Blombery, MBBS, Peter Maccallum Cancer Centre
Disclosures:
No relevant conflicts of interest to declare.
4:30 PM

Caroline Huber1*, Yumi Nakayama, PhD2*, Camille Soun1*, Noushin Mossadegh-Keller, PhD1*, Sophie Guia, PhD1*, Melanie Collin1*, Alexandre Sarrabay1*, Lionel Chasson1*, Lionel Spinelli, PhD1*, Bertrand Nadel, PhD3,4, Anita K. Gandhi, PhD5, Gabriel Brisou, MD, PhD1,6*, Patrick R. Hagner, PhD2* and Sandrine Roulland, PharmD, PhD1*

1Aix Marseille Université, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, France
2Bristol Myers Squibb, Summit, NJ
3Institut Carnot Calym, Lyon, France
4Centre D'Immunologie De Marseille-Luminy, Marseilles, France
5Hematology, Translational Medicine, Bristol Myers Squibb, Summit, NJ
6Institut Paoli-Calmettes, Marseille, France

4:45 PM

Ran Kong1*, Shi Feng2*, Cong Wang3*, Qingbo Hao2*, Yu Zhang4*, Jingjing Han5*, Xiaoyu Xie2*, Haiyang Wang2*, Jan Elsner6*, Derek Mendy6*, Michael Haughey6*, Paul Krenitsky6*, Veronique Plantevin-Krenitsky6*, Patrick Papa6*, Frank Mercurio6*, Weilin Xie6* and Xiangxiang Zhou, MD4

1Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, China
2Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China
3Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, AL, China
4Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
5Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
6Innovo Therapeutics, San Diego

5:00 PM

Lynda Groocock1*, Gauri Deb1*, Jinyi Zhu1*, Jim Gamez1*, Paola Castiglioni1*, Manuel Sanchez-Castillo2*, Justin Schumacher3*, Alicia Benitez Rondan2*, Diana Jankeel1*, Karla Martinez-Garcia1*, Scott Wood1*, Andy Christoforou1*, Carla Guarinos2*, Wei Zhang1*, Rama Krishna Narla1*, Christoph W. Zapf1*, Soraya Carrancio, PhD1*, Daniel W. Pierce4*, Mark Rolfe1, Neil Bence1*, Antonia Lopez-Girona1* and Deborah S. Mortensen1*

1Research and Development, Bristol Myers Squibb, San Diego, CA
2Center for Innovation and Translational Research Europe (CITRE), Bristol Myers Squibb, Seville, Spain
3Research and Development, Bristol Myers Squibb, New Brunswick, NJ
4Research and Development, Bristol Myers Squibb, Brisbane, CA

5:15 PM

Wenzhuo Zhuang1*, Yuchen Zhang2*, Chunxiao Yang3*, Linlin Qin1*, Ruijing Hu1*, Menglu Chen2*, Xinyuan Zhang2*, Qi Li2*, Xingping Lang3*, Si Chen3* and Bingzong Li, MD, PhD4

1Suzhou Medical College of Soochow University, Suzhou, China
2The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
3Suzhou Sano Precision Medicine Ltd, Suzhou, China
4Department of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

5:30 PM

Rachel Lawrence1*, Corinne Cayatte, PhD2*, Macarena Izuzquiza Fernandez3*, Scott Rata4*, Thomas Ciucci2*, Wen Lin2*, Abigail Lara2*, Nazli Jafarzadeh2*, Taylor Foreman2*, Sterling Payne5*, Harini Shandilya5*, Nisha Sambamurthy6*, Haibin Luo7*, Richard Stebbings1*, Simon Dovedi8*, Gullu Gorgun9*, Anthony Mato10*, Saso Cemerski2*, Mark Cobbold11* and Anas Younes10

1Safety Sciences, AstraZeneca, Early Oncology R&D, Cambridge, United Kingdom
2Immune Engagers, AstraZeneca, Early Oncology R&D, Gaithersburg, MD
3Clinical, AstraZeneca, Hematology R&D, Barcelona, Spain
4Translational DMPK, AstraZeneca, Early Oncology R&D, Waltham, MA
5Biologics Engineering, AstraZeneca, Early Oncology R&D, Gaithersburg, MD
6Translational Medicine, AstraZeneca, Hematology R&D, South San Francisco, CA
7Biopharmaceutical Development, BioPharmaceutical R&D, Gaithersburg, MD
8Immune Engagers, AstraZeneca, Early Oncology R&D, Cambridge, United Kingdom
9AstraZeneca Hematology R&D, Waltham, MA
10AstraZeneca Hematology R&D, New York, NY
11Immune Engagers, AstraZeneca, Early Oncology R&D, Waltham, MA

5:45 PM

Hui Yu1*, Yixin Qian2*, Weiping Liu3*, Lan Mi4*, Yun Huang5*, Rui Peng6*, Jiaowu Cao5*, Dingyao Hu5*, Jun Zhu, PhD7, Yuqin Song, MD8 and Mi Deng, PhD9*

1Lymphoma, Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), Beijing, China
2Peking university basic medical school, Beijing, China
3Peking University Cancer Hospital, Beijing, China
4Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China
5Beijing Cancer Hospital, Beijing, China
6Peking University School of Basic Medical Science, Beijing, China
7Department of Lymphoma, Peking University Cancer Hospital, Beijing, Beijing, China
8Department of Lymphoma, Peking University Cancer Hospital, BEIJING, China
9State Key Laboratory of Molecular Oncology, Beijing Key Laboratory of Carcinogenesis and Translational Research, Deng Mi Lab, Peking University Cancer Hospital & Institute, Beijing, Beijing, China

*signifies non-member of ASH